PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 54 filers reported holding PROQR THRAPEUTICS N V in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $445,845 | -44.5% | 342,958 | -30.8% | 0.00% | – |
Q2 2023 | $802,736 | -41.9% | 495,516 | -23.6% | 0.00% | – |
Q1 2023 | $1,382,067 | -1.4% | 648,858 | +71.4% | 0.00% | – |
Q4 2022 | $1,401,005 | +294.6% | 378,650 | -20.7% | 0.00% | – |
Q3 2022 | $355,000 | +14.1% | 477,713 | +19.8% | 0.00% | – |
Q2 2022 | $311,000 | +69.9% | 398,795 | +97.5% | 0.00% | – |
Q1 2022 | $183,000 | -37.5% | 201,904 | +451.3% | 0.00% | – |
Q4 2021 | $293,000 | -68.5% | 36,621 | -67.0% | 0.00% | – |
Q3 2021 | $930,000 | -64.1% | 111,070 | -71.1% | 0.00% | – |
Q2 2021 | $2,594,000 | -18.3% | 384,872 | -19.9% | 0.00% | – |
Q1 2021 | $3,176,000 | -25.4% | 480,563 | -52.6% | 0.00% | -100.0% |
Q4 2020 | $4,259,000 | +313.1% | 1,014,075 | +371.4% | 0.00% | – |
Q3 2020 | $1,031,000 | -56.5% | 215,109 | -44.8% | 0.00% | -100.0% |
Q2 2020 | $2,370,000 | +112.2% | 389,878 | +91.6% | 0.00% | – |
Q1 2020 | $1,117,000 | +6470.6% | 203,482 | +12113.8% | 0.00% | – |
Q4 2019 | $17,000 | +21.4% | 1,666 | -29.7% | 0.00% | – |
Q3 2019 | $14,000 | -22.2% | 2,371 | +18.3% | 0.00% | – |
Q2 2019 | $18,000 | -98.3% | 2,004 | -97.4% | 0.00% | – |
Q1 2019 | $1,088,000 | -78.0% | 78,457 | -75.0% | 0.00% | -100.0% |
Q4 2018 | $4,955,000 | -37.0% | 313,995 | -22.7% | 0.00% | -50.0% |
Q3 2018 | $7,862,000 | +270.7% | 406,284 | +39.8% | 0.00% | +100.0% |
Q2 2018 | $2,121,000 | +200.0% | 290,575 | +26.3% | 0.00% | – |
Q1 2018 | $707,000 | +23.4% | 230,000 | +29.5% | 0.00% | – |
Q4 2017 | $573,000 | +16.7% | 177,600 | +75.3% | 0.00% | – |
Q3 2017 | $491,000 | +52.5% | 101,300 | +63.7% | 0.00% | – |
Q2 2017 | $322,000 | -33.7% | 61,872 | -36.3% | 0.00% | – |
Q1 2017 | $486,000 | -4.7% | 97,106 | -6.6% | 0.00% | – |
Q4 2016 | $510,000 | +125.7% | 104,022 | +207.8% | 0.00% | – |
Q3 2016 | $226,000 | +53.7% | 33,800 | +11.6% | 0.00% | – |
Q2 2016 | $147,000 | +2840.0% | 30,300 | +2930.0% | 0.00% | – |
Q1 2016 | $5,000 | -99.0% | 1,000 | -97.0% | 0.00% | – |
Q3 2015 | $488,000 | -21.9% | 33,516 | -10.6% | 0.00% | – |
Q2 2015 | $625,000 | -38.4% | 37,471 | -19.2% | 0.00% | – |
Q1 2015 | $1,015,000 | +12.7% | 46,370 | +11.5% | 0.00% | – |
Q4 2014 | $901,000 | +231.2% | 41,571 | +162.4% | 0.00% | – |
Q3 2014 | $272,000 | – | 15,845 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 1,237,400 | $5,197,000 | 1.55% |
Prosight Management, LP | 255,000 | $1,071,000 | 0.50% |
RTW INVESTMENTS, LP | 5,009,768 | $21,041,000 | 0.35% |
Kerrisdale Advisers, LLC | 453,182 | $1,903,000 | 0.15% |
Artal Group S.A. | 1,196,218 | $5,024,000 | 0.11% |
COWEN AND COMPANY, LLC | 285,696 | $1,200,000 | 0.11% |
Golden Green, Inc. | 16,999 | $71,000 | 0.07% |
APOGEM CAPITAL LLC | 15,855 | $67,000 | 0.04% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,550,062 | $19,110,000 | 0.04% |
ALTRINSIC GLOBAL ADVISORS LLC | 241,360 | $1,014,000 | 0.03% |